secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001193125-25-147339
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO
--------------------------------------------------------------------------------

- License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.
- Private Placement: $175M gross from pre-funded warrants to buy 700M shares at $0.25/warrant; closing expected June 27, 2025.
- CEO change: Robert Ang resigned; Jean-Paul Kress (ex-MorphoSys CEO) appointed CEO and Chairman. Dr. Ang stays as advisor through October.
- Cambridge lease terminated: $8.5M termination fee paid; $2.4M letter of credit to be returned. Lease was set to expire in 2030.
- Stockholders representing ~63% voting power signed support agreements to approve share issuance and charter amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525147339/0001193125-25-147339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525147339/d27026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-147339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer